CYP3A4 activity in four different animal species liver microsomes using 7-benzyloxyquinoline and HPLC/spectrofluorometric determination

被引:13
作者
Baririan, N
Desager, JP
Petit, M
Horsmans, Y
机构
[1] Catholic Univ Louvain, Hop Univ St Luc, Clin Pharmacol Unit, B-1200 Brussels, Belgium
[2] Catholic Univ Louvain, Dept Gastroenterol, B-1200 Brussels, Belgium
关键词
CYP3A(4); HPLC; 7-benzyloxyquinoline; midazolam; ketoconazole;
D O I
10.1016/j.jpba.2005.07.002
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Some microplate-based direct assays with different fluorometric substrates have been developed, among which 7-benzyloxyquinotine (BOQ) has demonstrated the highest degree of selectivity for CYP3A subfamily. In our study, we firstly developed and validated an efficient, fast and cheap HPLC/spectrofluorometric analytical method to quantify 7-hydroxyquinoline (BOQ metabolite). Secondly, BOQ oxidation rate (1.95 +/- 10.24 mu M/mg protein/min) was compared to that of midazolam (MDZ) (1.4 +/- 0.21 mu M/mg protein/min), an other specific CYP3A probe. However, the difference did not reach statistically significance (test of Sign; p = 0.125, two tailed). Thirdly, the potential use of BOQ in other species than the rat (mouse, dog and monkey) was studied. The highest BOQ activity was observed in rat microsomes (3.75 mu mol/mg protein/min) with lower P450 content (0.3 nmol/mg protein) compared to other species. Finally, the effect of CYP3A enzymes-selective inhibitor ketoconazole on the dealkylation of BOQ in control and dexamethasone (DM)-treated rat microsomes was studied. Ketoconazole inhibition potency was greater in control (IC50 approximate to 21.6 mu M) compared to DM induced (IC50 approximate to 32.3 mu M) microsomes. At concentrations greater than that considered to be enzyme-selective (e.g., 10-30 mu M), ketoconazole inhibitory activity did not rise significantly, and at the maximal concentration tested (1000 mu M) a nearly similar inhibition (76%) was observed than that at 50 mu M concentration (68.2%). (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:211 / 214
页数:4
相关论文
共 20 条
[1]  
[Anonymous], 2003, OFFICIAL METHODS ANA
[2]   Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe [J].
Chauret, N ;
Tremblay, N ;
Lackman, RL ;
Gauthier, JY ;
Silva, JM ;
Marois, J ;
Yergey, JA ;
Nicoll-Griffith, DA .
ANALYTICAL BIOCHEMISTRY, 1999, 276 (02) :215-226
[3]  
Desager JP, 2003, DRUG METAB REV, V35, P126
[4]   Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism -: Focus on in vitro studies [J].
Donato, MT ;
Castell, JV .
CLINICAL PHARMACOKINETICS, 2003, 42 (02) :153-178
[5]   Sensitive assay for midazolam and its metabolite 1′-hydroxymidazolam in human plasma by capillary high-performance liquid chromatography [J].
Eeckhoudt, SL ;
Desager, JP ;
Horsmans, Y ;
De Winne, AJ ;
Verbeeck, RK .
JOURNAL OF CHROMATOGRAPHY B, 1998, 710 (1-2) :165-171
[6]   Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes and hepatocytes [J].
Ghosal, A ;
Hapangama, N ;
Yuan, Y ;
Lu, XW ;
Horne, D ;
Patrick, JE ;
Zbaida, S .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2003, 24 (09) :375-384
[7]   Cytochrome P-450 3A4: Regulation and role in drug metabolism [J].
Guengrich, FP .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :1-17
[8]   7-benzyloxyquinoline oxidation by P450eryF A245T: Finding of a new fluorescent substrate probe [J].
Khan, KK ;
Halpert, JR .
CHEMICAL RESEARCH IN TOXICOLOGY, 2002, 15 (06) :806-814
[9]  
Leclercq I, 1997, HEPATOLOGY, V26, P1182
[10]  
Lu P, 2001, DRUG METAB DISPOS, V29, P1473